Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T25698
|
|||||
Target Name |
Pseudomonas Lipopolysaccharide (Pseudo LPS)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Medical/surgical procedure injury [ICD-11: PK80-PK81] | |||||
2 | Pneumonia [ICD-11: CA40] | |||||
3 | Glanders [ICD-11: 1B92] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | Panobacumab | Drug Info | Phase 2 | Ventilator-associated pneumonia | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | Panobacumab | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. | |||||
REF 2 | ClinicalTrials.gov (NCT00851435) Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.